Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Fenebrutinib targets cells in the immune system known as B cells and microglia
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
FIBROSARC did not meet its primary PFS endpoint in the final analysi
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
This partnership has led to a 10% boost in delivery speed
Subscribe To Our Newsletter & Stay Updated